BACKGROUND: T-cell large granular lymphocytic leukemia is a rare lymphoproliferative disorder characterized by the expansion of clonal CD3+CD8+ cytotoxic T lymphocytes (CTLs) and often associated with autoimmune disorders and immune-mediated cytopenias. METHODS: We used next-generation exome sequencing to identify somatic mutations in CTLs from an index patient with large granular lymphocytic leukemia. Targeted resequencing was performed in a well-characterized cohort of 76 patients with this disorder, characterized by clonal T-cell-receptor rearrangements and increased numbers of large granular lymphocytes. RESULTS: Mutations in the signal transducer and activator of transcription 3 gene (STAT3) were found in 31 of 77 patients (40%) with large granular lymphocytic leukemia. Among these 31 patients, recurrent mutational hot spots included Y640F in 13 (17%), D661V in 7 (9%), D661Y in 7 (9%), and N647I in 3 (4%). All mutations were located in exon 21, encoding the Src homology 2 (SH2) domain, which mediates the dimerization and activation of STAT protein. The amino acid changes resulted in a more hydrophobic protein surface and were associated with phosphorylation of STAT3 and its localization in the nucleus. In vitro functional studies showed that the Y640F and D661V mutations increased the transcriptional activity of STAT3. In the affected patients, downstream target genes of the STAT3 pathway (IFNGR2, BCL2L1, and JAK2) were up-regulated. Patients with STAT3 mutations presented more often with neutropenia and rheumatoid arthritis than did patients without these mutations. CONCLUSIONS: The SH2 dimerization and activation domain of STAT3 is frequently mutated in patients with large granular lymphocytic leukemia; these findings suggest that aberrant STAT3 signaling underlies the pathogenesis of this disease. (Funded by the Academy of Finland and others.).
BACKGROUND: T-cell large granular lymphocytic leukemia is a rare lymphoproliferative disorder characterized by the expansion of clonal CD3+CD8+ cytotoxic T lymphocytes (CTLs) and often associated with autoimmune disorders and immune-mediated cytopenias. METHODS: We used next-generation exome sequencing to identify somatic mutations in CTLs from an index patient with large granular lymphocytic leukemia. Targeted resequencing was performed in a well-characterized cohort of 76 patients with this disorder, characterized by clonal T-cell-receptor rearrangements and increased numbers of large granular lymphocytes. RESULTS: Mutations in the signal transducer and activator of transcription 3 gene (STAT3) were found in 31 of 77 patients (40%) with large granular lymphocytic leukemia. Among these 31 patients, recurrent mutational hot spots included Y640F in 13 (17%), D661V in 7 (9%), D661Y in 7 (9%), and N647I in 3 (4%). All mutations were located in exon 21, encoding the Src homology 2 (SH2) domain, which mediates the dimerization and activation of STAT protein. The amino acid changes resulted in a more hydrophobic protein surface and were associated with phosphorylation of STAT3 and its localization in the nucleus. In vitro functional studies showed that the Y640F and D661V mutations increased the transcriptional activity of STAT3. In the affected patients, downstream target genes of the STAT3 pathway (IFNGR2, BCL2L1, and JAK2) were up-regulated. Patients with STAT3 mutations presented more often with neutropenia and rheumatoid arthritis than did patients without these mutations. CONCLUSIONS: The SH2 dimerization and activation domain of STAT3 is frequently mutated in patients with large granular lymphocytic leukemia; these findings suggest that aberrant STAT3 signaling underlies the pathogenesis of this disease. (Funded by the Academy of Finland and others.).
Authors: Pearlie K Epling-Burnette; Fanqi Bai; Sheng Wei; Pratima Chaurasia; Jeffrey S Painter; Nancy Olashaw; Andrew Hamilton; Said Sebti; Julie Y Djeu; Thomas P Loughran Journal: Oncogene Date: 2004-12-09 Impact factor: 9.867
Authors: Ravi Kothapalli; Susan B Nyland; Irina Kusmartseva; Ratna D Bailey; Tylee M McKeown; Thomas P Loughran Journal: Int J Oncol Date: 2005-02 Impact factor: 5.650
Authors: T C Gentile; K G Hadlock; A H Uner; B Delal; E Squiers; S Crowley; R C Woodman; S K Foung; B J Poiesz; T P Loughran Journal: Br J Haematol Date: 1998-06 Impact factor: 6.998
Authors: E Papaemmanuil; M Cazzola; J Boultwood; L Malcovati; P Vyas; D Bowen; A Pellagatti; J S Wainscoat; E Hellstrom-Lindberg; C Gambacorti-Passerini; A L Godfrey; I Rapado; A Cvejic; R Rance; C McGee; P Ellis; L J Mudie; P J Stephens; S McLaren; C E Massie; P S Tarpey; I Varela; S Nik-Zainal; H R Davies; A Shlien; D Jones; K Raine; J Hinton; A P Butler; J W Teague; E J Baxter; J Score; A Galli; M G Della Porta; E Travaglino; M Groves; S Tauro; N C Munshi; K C Anderson; A El-Naggar; A Fischer; V Mustonen; A J Warren; N C P Cross; A R Green; P A Futreal; M R Stratton; P J Campbell Journal: N Engl J Med Date: 2011-09-26 Impact factor: 91.245
Authors: Madhu P Menon; Alina Nicolae; Hillary Meeker; Mark Raffeld; Liqiang Xi; Armin G Jegalian; Douglas C Miller; Stefania Pittaluga; Elaine S Jaffe Journal: Am J Surg Pathol Date: 2015-12 Impact factor: 6.394
Authors: Sarah Walker; Chen Wang; Trent Walradt; Bok Sil Hong; Justin R Tanner; Jonathan L Levinsohn; Gerald Goh; Antonio Subtil; Stuart R Lessin; Warren R Heymann; Eric C Vonderheid; Brett A King; Richard P Lifton; Jaehyuk Choi Journal: Blood Date: 2015-12-23 Impact factor: 22.113
Authors: Claudia Mertens; Bhagwattie Haripal; Sebastian Klinge; James E Darnell Journal: Proc Natl Acad Sci U S A Date: 2015-11-09 Impact factor: 11.205
Authors: HeeJin Cheon; Karolina H Dziewulska; Katharine B Moosic; Kristine C Olson; Alejandro A Gru; David J Feith; Thomas P Loughran Journal: Curr Hematol Malig Rep Date: 2020-04 Impact factor: 3.952